Exact Sciences Corp ((EXAS)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Exact Sciences Corp is currently recruiting participants for its study titled ‘Falcon – The Exact Sciences Multicancer Early Detection (MCED) Real World Evidence (RWE) Registry.’ The primary objective of this study is to gather real-world evidence on the performance of the Exact Sciences MCED test, which is significant for advancing early cancer detection methods.
The intervention being tested is the Exact Sciences Multicancer Early Detection (MCED) Test, a device designed to detect cancer-related alterations in circulating tumor DNA and protein levels using blood samples.
This observational study follows a cohort model with a prospective time perspective. It aims to observe and collect data from patients undergoing the MCED test without any specific allocation or masking procedures.
The study began on August 19, 2024, with the latest update submitted on May 30, 2025. These dates indicate the study’s progress and ongoing data collection efforts.
The study’s progress could positively influence Exact Sciences Corp’s stock performance by demonstrating the potential of its MCED test in early cancer detection. This could enhance investor confidence, especially in a competitive market where early detection technologies are highly valued.
The study is ongoing, with further details available on the ClinicalTrials portal.